↓ Skip to main content

N-acetylcysteine in COPD: why, how, and when?

Overview of attention for article published in Multidisciplinary Respiratory Medicine, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#29 of 307)
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

news
1 news outlet
twitter
13 X users
video
1 YouTube creator

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
N-acetylcysteine in COPD: why, how, and when?
Published in
Multidisciplinary Respiratory Medicine, February 2016
DOI 10.1186/s40248-016-0039-2
Pubmed ID
Authors

Claudio M. Sanguinetti

Abstract

Oxidants have long been recognized to have an important role in the pathogenesis of COPD, and in this cigarette smoke has a strong responsibility, because it generates a conspicuous amount of oxidant radicals able to modify the structure of the respiratory tract and to enhance several mechanisms that sustain lung inflammation in COPD. In fact, oxidative stress is highly increased in COPD and natural antioxidant capacities, mainly afforded by reduced glutathione, are often overcome. Thus an exogenous supplementation of antioxidant compounds is mandatory to at least partially counteract the oxidative stress. For this purpose N-acetylcysteine has great potentialities due to its capacity of directly contrasting oxidants with its free thiols, and to the possibility it has of acting as donor of cysteine precursors aimed at glutathione restoration. Many studies in vitro and in vivo have already demonstrated the antioxidant capacity of NAC. Many clinical studies have long been performed to explore the efficacy of NAC in COPD with altern results, especially when the drug was used at very low dosage and/or for a short period of time. More recently, several trials have been conducted to verify the appropriateness of using high-dose NAC in COPD, above all to decrease the exacerbations rate. The results have been encouraging, even if some of the data come from the most widely sized trials that have been conducted in Chinese populations. Although other evidence should be necessary to confirm the results in other populations of patients, high-dose oral NAC nevertheless offers interesting perspectives as add-on therapy for COPD patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Russia 1 1%
Unknown 90 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 19%
Student > Master 13 14%
Researcher 10 11%
Other 9 10%
Student > Postgraduate 7 8%
Other 14 15%
Unknown 21 23%
Readers by discipline Count As %
Medicine and Dentistry 23 25%
Pharmacology, Toxicology and Pharmaceutical Science 11 12%
Agricultural and Biological Sciences 7 8%
Biochemistry, Genetics and Molecular Biology 6 7%
Nursing and Health Professions 6 7%
Other 15 16%
Unknown 23 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2024.
All research outputs
#2,030,466
of 25,374,647 outputs
Outputs from Multidisciplinary Respiratory Medicine
#29
of 307 outputs
Outputs of similar age
#34,885
of 405,859 outputs
Outputs of similar age from Multidisciplinary Respiratory Medicine
#3
of 8 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 405,859 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.